Document:

Exhibit 10.3

Exhibit 10.3
[ZELTIQ LOGO]
January 5, 2012 - revised January 16, 2012 and January 18, 2012
John Howe 
4332 Second Street
Pleasanton, CA 94566 

		
	Re:
	Separation from ZELTIQ Aesthetics, Inc.

Dear John:
This letter confirms your termination from ZELTIQ Aesthetics, Inc. (the “Company”), and explains the details of your separation from employment as well as the severance benefits the Company is offering to you.
      A.     Termination without Cause; Separation Date.  Your termination is without Cause, as that term is defined in your employment agreement with the Company dated April 29, 2010 (“Employment Agreement”).  We have agreed, however, that you may characterize your termination publicly (e.g., to prospective or future employers) as a voluntary resignation/retirement.  Effective January 5, 2012, you will “resign” your position as Chief Financial Officer but will remain employed by the Company until your effective “retirement” on January 23, 2012 (“Separation Date”).   Nevertheless, you will not be expected to perform any services for the Company after January 20, 2012, and you represent and warrant that you have not done so.
      You acknowledge that you have been given your final paycheck (paying you up to and including January 20, 2012) and paid all outstanding salary amounts and any accrued, but unused, vacation time.  You also will be eligible to convert your medical and dental insurance coverage under COBRA, and will be provided with information describing this conversion election.  Further, the Company will not challenge any claim by you for unemployment benefits.
B.    Separation Benefits.  Pursuant to Section 6 of your Employment Agreement, the Company will provide to you the following severance benefits in exchange for your agreement to waive all claims against the Company, whether you have any claims or not: 
(i)Severance.  The Company will pay you severance in the amount of One Hundred and Fifty Thousand Dollars ($150,000), less applicable withholdings, which is equivalent to six (6) months of your current base salary (“Severance”).  The Severance will be paid over six (6) months (the “Severance Period”) in the form of salary continuation, in accordance with the Company's regular payroll practices, beginning on the first payroll following expiration of the 7-day revocation period discussed in Section J.   
(ii)      COBRA Coverage.  Subject to your timely conversion election, the Company will pay the premiums for your COBRA coverage (including medical and dental) at the rates then in effect for active employees (subject to any subsequent changes in the rates that are generally applicable to the Company's active employees) until the earlier of the six-month anniversary of your Separation Date or the date you become covered under another employer's group health plan (“COBRA Subsidy”).  
Although it is under no legal obligation to do so, the Company also will provide to you the following additional separation benefits in exchange for your waiver and release of claims, and your agreement to be reasonably available to the Company during the Severance Period (via phone or electronic means) to help in good faith transition and respond to requests for information regarding ongoing projects and business-related matters: 
(iii)  2011 Target Bonus.  In the event that the Company determines, within its sole discretion, that the single revenue target set forth in the amended 2011 “second half” Bonus Plan has been met (or partially met) and target bonuses have been earned (or partially earned), the Company will pay you a 2011 Target Bonus equal to the same percentage of your “at plan” percentage of base salary that will be applied uniformly to all eligible employees (“Target Bonus”).  Any Target Bonus will be subject to applicable withholdings and paid no later than March 15, 2012, provided that the 7-day revocation period discussed below has expired and you have not revoked this Agreement.

(iv)  Attorney's Fees.  The Company will reimburse you for any reasonable and actual attorneys' fees that you incur or will incur in connection with your separation from employment and the negotiation of this Agreement (“Attorneys' Fees”); provided, however, that the amount of the Attorneys' Fees shall not exceed Three Thousand Dollars ($3,000.00).  Within thirty (30) days of the Effective Date of this Agreement, you will submit to the Company an invoice from your counsel verifying the amount of Attorneys' Fees you incurred, and the Company will reimburse you for the Attorneys' Fees within ten (10) business days of receiving this invoice.  The Company will have no obligation to reimburse you for the Attorneys' Fees if you fail to submit an invoice from your counsel as provided for in this Section, or if you revoke this Agreement during the 7-day period discussed in Section J.   
Except for the separation terms proposed in this Agreement, you will not be entitled to any compensation, benefits or other perquisites of employment after your last day of employment.  Any stock options previously granted to you are governed by the terms and conditions of the Company's 2005 Stock Incentive Plan.  You agree that the Company's provision of separation benefits to you shall not be deemed as an admission of liability by the Company.
C.    Mutual Release.  In exchange for the separation benefits described in Section B, and the mutual release set forth herein, you agree that you and your representatives waive all claims of any kind, known and unknown, which you may now have or have ever had against ZELTIQ Aesthetics, Inc., its affiliated, related, parent and subsidiary corporations, and its and their present and former directors, officers, and employees (“Released Parties”).  This release includes all claims arising from your employment with the Company and its termination, including employment discrimination claims under the California Fair Employment and Housing Act, Title VII, the Age Discrimination in Employment Act (“ADEA”), and any other state or federal law.  
The Company agrees to completely release you and your representatives from all claims of any kind, known and unknown, including all claims arising from your employment with the Company and its termination, which the Company may now have or has ever had against you (“Company's Released Claims.”).   
Notwithstanding the foregoing, the parties acknowledge and agree that they are not waiving or being required to waive any right or claim that cannot be waived as a matter of law.  Additionally, this release shall not apply to any right or claim you may have to indemnification under California Labor Code section 2802 or other state or federal law.  
D.     Section 1542 Waiver.   Because the parties' mutual release specifically covers known and unknown claims, you (including your representatives) and the Company understand and acknowledge that they are waiving their rights under Section 1542 of the California Civil Code or any comparable law of any other jurisdiction.  Section 1542 states:  "A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement to the debtor."
E.  Covenant Not to Sue.  You and the Company agree not to initiate or cause to be initiated any lawsuit, investigation or proceeding of any kind concerning the claims released by this Agreement against one another, or to voluntarily participate in one except as required by law.  
F.     Confidential Agreement. You and the Company also understand and agree that this Agreement shall be maintained in strict confidence, and that the parties shall not disclose any of its terms to another person unless required by law.  Notwithstanding the foregoing, you may disclose the terms of this Agreement to (i) your spouse, if any, and, for legitimate business reasons, (ii) your attorneys or tax advisors.  For legitimate business reasons, the Company may disclose the terms of this Agreement to its attorneys, tax advisors or others within the Company who have a legitimate “need to know.”
G.     Nondisparagement.  You agree not to disparage ZELTIQ Aesthetics, Inc. or any of its affiliates, including their business reputations or business relationships, to anyone or any entity, including, without limitation, press or media.  The Company's CEO, Gordie Nye, agrees not to disparage you, including your business reputation or relationships, to anyone or any entity, including, without limitation, press or media.
H.     Return of Company Property; Termination Certificate.  You agree to return all the Company's materials in your possession, including keys and computer(s), as soon as possible.  You also agree to sign and return the Termination Certificate to the Confidential Information and Inventions Agreement you entered into during your employment, and understand that even after your employment with the Company ends, you must comply with your continuing obligations under that Agreement, including your obligation to maintain the confidentiality of the Company's confidential and proprietary information.
I.    Miscellaneous.  This Agreement, the Company's 2005 Stock Incentive Plan, and the Confidential Information and Inventions Agreement contain all of our agreements and understandings and fully supersede any prior agreements or 

understandings that we may have had regarding your employment with the Company or its termination.  This Agreement shall be governed by California law and may be amended only in a written document signed by you and the Company's CEO.  If any term in this Agreement is unenforceable, the remainder of the Agreement will remain enforceable.  This Agreement shall be binding upon and shall inure to the benefit of the parties and their respective heirs, successors, attorneys and permitted assigns.  You agree, however, that you will not assign any rights or obligations under this Agreement, and any such purported assignment shall be null and void.  
J.    Waiver.  You agree that you have been advised that you have 21 days to consider this Agreement (but may sign it at any time beforehand if you so desire), and that any material or immaterial revisions to this Agreement shall not restart this 21-day period.  You also acknowledge that you have been advised to consult an attorney in considering this Agreement, and in fact have consulted an attorney.  You also understand that you can revoke this Agreement within 7 days of signing it by sending a certified letter to that effect to me.  Notwithstanding the foregoing, you understand and agree that the portion of this Agreement that pertains to the release of claims under the ADEA shall not become effective or enforceable and no funds shall be exchanged until the 7-day revocation period has expired, but that all other provisions of this Agreement will become effective upon its execution by the parties (“Effective Date”).
If you have any questions, please feel free to call me.  We wish you the very best in your future endeavors.

Very truly yours,

	
	
	 

	/s/ Gordie Nye

	Gordie Nye

	Chief Executive Officer

To accept the severance package described above, please sign below and return this letter to me on or before February 10, 2012.  Please do not sign before your Separation Date.

AGREED AND ACCEPTED:

 	
					
	 
	 
	 
	 
	 

	Dated: 1/24/2012
	 
	 
	 
	/s/ John Howe

	 
	 
	 
	 
	John HoweExhibit 10.4

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Exhibit 10.4
AMENDMENT TO DISTRIBUTION AGREEMENT BY AND BETWEEN ZELTIQ AESTHETICS, INC. and ADVANCE MEDICAL INC.
This Amendment (“Amendment”) to the Distribution Agreement, dated effective as of March 18, 2011 (the “Agreement”) by and between Zeltiq Aesthetics, Inc., a company incorporated under the laws of Delaware (“Zeltiq”) and ADVANCE Medical, Inc., a company incorporated under the laws of Delaware (“Distributor”), is made and entered into effective as of February 27, 2012.  Capitalized terms used but not otherwise defined herein shall have the same meanings as set forth in the Agreement.  
RECITALS
WHEREAS, Distributor and Zeltiq wish to make certain amendments to the Agreement, as hereinafter set forth.
NOW, THEREFORE, for good and valuable consideration, the adequacy and receipt of which is hereby acknowledged, Distributor and Zeltiq agree to amend the Agreement as follows:
		
	1.
	Amendment to Section 1.  Section 1 of the Agreement is hereby amended by:

(a)    deleting in the first sentence of subsection (h) the word “and” immediately preceding roman numerate (ii) and replacing it with a comma, and adding in the first sentence of subsection (h) after the “(“UM”))” the phrase “and (iii) BIOGEN” and
(b)    deleting the last sentence of subsection (h) and replacing it as follows:
“Distributor agrees that Zeltiq has the right to revoke the ability of Distributor to appoint and use any subdistributor to market, sell and distribute the Products in the event of to (i) any breach of the agreement by Distributor or subdistributor; (ii) Distributor's or subdistributor's violation of any applicable law or regulatory requirement; (iii) engagement by Distributor or subdistributor in any unlawful activity; (iv) subdistributor's or its designees' sale, advertising, solicitation or other activity in competition with the Products or (v) any conduct by Distributor or subdistributor that reflects negatively on the reputation, usefulness, or acceptance of Zeltiq or the Products.”
		
	2.
	Amendment to Section 2.  Section 2 of the Agreement is hereby amended by deleting subsection (d) in its entirety and replacing it as follows:

“(d) Quarterly Quota. Each calendar quarter during the Term of this Agreement, Distributor shall purchase a minimum quantity of Products equal to the amounts set forth on Exhibit A, Section 3 (the “Quarterly Quota”) based upon the then current Purchase Prices (as defined below). If Distributor fails to meet the Quarterly Quota for any calendar quarter, Zeltiq may, upon written notice to Distributor, at Zeltiq's option, either convert Distributor's exclusive rights in the Territory to non exclusive rights for the remainder of the Term or terminate this Agreement in accordance with Section 6(b).” 
		
	3.
	Amendment to Section 4.  Section 4 of the Agreement is hereby amended by:

(a)     deleting the period at the end of the second sentence of subsection (b) and replacing it as follows:
“; provided, however, that any increase in the Purchase Price shall be equal to or less than the then average increase in Product prices offered to all other Zeltiq distributors.” and
(b)    deleting subparagraph (f) in its entirety and replacing it as follows:
[ * ]
		
	4.
	Amendment to Section 6.  Section 6 of the Agreement is hereby amended by:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

(a)    deleting the first sentence of subparagraph (a) and replacing it as follows:
“The Term shall commence on the Effective Date and shall continue through December 31, 2018, unless terminated earlier under the provisions of this Section 6 (the “Initial Term”).”;
(b)    deleting the first sentence of subparagraph (d) and replacing it as follows:
“If Zeltiq undergoes a Change of Control (as defined below) at any time, then the acquirer of or successor in interest in Zeltiq shall assume all of the obligations and liabilities under this Agreement unless otherwise mutually agreed in writing by such acquirer or successor and Distributor.” and
		
	(c)
	deleting the last sentence of subparagraph (d) and replacing it as follows:

“The term “Change of Control” shall mean, with respect to any party, such party's direct or indirect acquisition by, or merger into, a third party, the sale of all or substantially all of the assets of such party, or a transaction pursuant to which the owners or shareholders of such party that hold more than fifty percent (50%) of such party's equity or other ownership interest prior to the transaction cease to own at least fifty percent (50%) of such interest after the transaction; provided that a Change of Control shall not include any private equity buyout of such party or its shareholders principally for financial purposes or any transaction or series of transactions principally for bona fide equity financing purposes in which cash is received by such party or any successor or indebtedness of such party is cancelled or converted or a combination thereof.”
		
	5.
	Amendment to Exhibit A.  Exhibit A to the Agreement is hereby amended by:

(a)    adding the words “and Mexico” after the words “Exclusive: Brazil” under the heading “TERRITORY” in Section 1;
(b)    adding a footnote to the end of the table in Section 2 as follows:
[ * ] and
(c)    deleting Section 3 in its entirety and replacing it as follows:
“3. Quarterly Quota
	
						
	Calendar Year
	Q1
	Q2
	Q3
	Q4
	Total

	2012
	[ * ]
	[ * ]
	[ * ]
	[ * ]
	[ * ]

	2013
	[ * ]
	[ * ]
	[ * ]
	[ * ]
	[ * ]

	2014
	[ * ]
	[ * ]
	[ * ]
	[ * ]
	[ * ]

	2015
	[ * ]
	[ * ]
	[ * ]
	[ * ]
	[ * ]

	2016
	[ * ]
	[ * ]
	[ * ]
	[ * ]
	[ * ]

	2017
	[ * ]
	[ * ]
	[ * ]
	[ * ]
	[ * ]

	2018
	[ * ]
	[ * ]
	[ * ]
	[ * ]
	[ * ]

		
	6.
	In the event of a conflict between the Agreement and this Amendment, the terms of this Amendment shall govern.  In the event of a conflict between the Confidentiality Agreement by and between Zeltiq and Distributor and this Amendment, the terms of the Confidentiality Agreement shall govern.  

		
	7.
	Except as and to the extent specifically modified, amended or supplemented hereby, the Agreement shall remain in full force and effect.  

[Signatures appear on next page]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

IN WITNESS WHEREOF, intending to be legally bound hereby, the parties have caused this Amendment to be signed in their respective names by their duly authorized representatives as of the date first above written.

	
			
	Distributor:  Advance Medical Inc.
By:/s/ Fred Aslan
Authorized Signature
FRED ASLAN/CEO
Printed Name/Title
2/27/2012
Date
	 
	Zeltiq:  Zeltiq Aesthetics, Inc.
By: /s/ Josh Brumm
Authorized Signature
JOSH BRUMM/CFO
Printed Name/Title
2/27/2012
Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]